GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (FRA:RYIS) » Definitions » Equity-to-Asset

Sunesis Pharmaceuticals (FRA:RYIS) Equity-to-Asset : 0.86 (As of Dec. 2020)


View and export this data going back to 2007. Start your Free Trial

What is Sunesis Pharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Sunesis Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2020 was €16.39 Mil. Sunesis Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2020 was €19.11 Mil.

The historical rank and industry rank for Sunesis Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

FRA:RYIS's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.66
* Ranked among companies with meaningful Equity-to-Asset only.

Sunesis Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for Sunesis Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals Equity-to-Asset Chart

Sunesis Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.49 0.63 0.26 0.74 0.86

Sunesis Pharmaceuticals Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.74 0.70 0.63 0.87 0.86

Competitive Comparison of Sunesis Pharmaceuticals's Equity-to-Asset

For the Biotechnology subindustry, Sunesis Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunesis Pharmaceuticals's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunesis Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Sunesis Pharmaceuticals's Equity-to-Asset falls into.



Sunesis Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Sunesis Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2020 is calculated as

Equity to Asset (A: Dec. 2020 )=Total Stockholders Equity/Total Assets
=16.388/19.109
=0.86

Sunesis Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2020 is calculated as

Equity to Asset (Q: Dec. 2020 )=Total Stockholders Equity/Total Assets
=16.388/19.109
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sunesis Pharmaceuticals  (FRA:RYIS) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Sunesis Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunesis Pharmaceuticals (FRA:RYIS) Business Description

Traded in Other Exchanges
N/A
Address
395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Sunesis Pharmaceuticals (FRA:RYIS) Headlines

No Headlines